JP3953106B2 - 新規なタキソイド、その製造及びそれを含有する製薬学的組成物 - Google Patents

新規なタキソイド、その製造及びそれを含有する製薬学的組成物 Download PDF

Info

Publication number
JP3953106B2
JP3953106B2 JP52336197A JP52336197A JP3953106B2 JP 3953106 B2 JP3953106 B2 JP 3953106B2 JP 52336197 A JP52336197 A JP 52336197A JP 52336197 A JP52336197 A JP 52336197A JP 3953106 B2 JP3953106 B2 JP 3953106B2
Authority
JP
Japan
Prior art keywords
group
carbon atoms
hydrogen atom
alkyl
together form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP52336197A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000502671A (ja
Inventor
ブシヤール,エルベ
コメルソン,アラン
Original Assignee
ローン―プーラン・ロレ・ソシエテ・アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ローン―プーラン・ロレ・ソシエテ・アノニム filed Critical ローン―プーラン・ロレ・ソシエテ・アノニム
Publication of JP2000502671A publication Critical patent/JP2000502671A/ja
Application granted granted Critical
Publication of JP3953106B2 publication Critical patent/JP3953106B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP52336197A 1995-12-22 1996-12-19 新規なタキソイド、その製造及びそれを含有する製薬学的組成物 Expired - Fee Related JP3953106B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR95/15379 1995-12-22
FR9515379A FR2742751B1 (fr) 1995-12-22 1995-12-22 Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
PCT/FR1996/002031 WO1997023473A1 (fr) 1995-12-22 1996-12-19 Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
JP2000502671A JP2000502671A (ja) 2000-03-07
JP3953106B2 true JP3953106B2 (ja) 2007-08-08

Family

ID=9485871

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52336197A Expired - Fee Related JP3953106B2 (ja) 1995-12-22 1996-12-19 新規なタキソイド、その製造及びそれを含有する製薬学的組成物

Country Status (40)

Country Link
US (1) US5728849A (OSRAM)
EP (1) EP0876362B1 (OSRAM)
JP (1) JP3953106B2 (OSRAM)
KR (1) KR100500351B1 (OSRAM)
CN (1) CN1103766C (OSRAM)
AR (1) AR005197A1 (OSRAM)
AT (1) ATE250593T1 (OSRAM)
AU (1) AU712597B2 (OSRAM)
BG (1) BG63204B1 (OSRAM)
BR (1) BR9612135A (OSRAM)
CA (1) CA2238884C (OSRAM)
CO (1) CO4520184A1 (OSRAM)
CZ (1) CZ294972B6 (OSRAM)
DE (1) DE69630145T2 (OSRAM)
DK (1) DK0876362T3 (OSRAM)
DZ (1) DZ2149A1 (OSRAM)
EA (1) EA001533B1 (OSRAM)
ES (1) ES2202490T3 (OSRAM)
FR (1) FR2742751B1 (OSRAM)
HU (1) HU225032B1 (OSRAM)
IL (1) IL124994A (OSRAM)
IN (4) IN186768B (OSRAM)
MA (1) MA26412A1 (OSRAM)
MX (1) MX9804688A (OSRAM)
MY (1) MY113934A (OSRAM)
NO (1) NO317358B1 (OSRAM)
NZ (1) NZ324337A (OSRAM)
OA (1) OA10700A (OSRAM)
PE (1) PE25198A1 (OSRAM)
PL (1) PL189311B1 (OSRAM)
PT (1) PT876362E (OSRAM)
RO (1) RO116194B1 (OSRAM)
SK (1) SK282835B6 (OSRAM)
TN (1) TNSN96169A1 (OSRAM)
TR (1) TR199801179T2 (OSRAM)
TW (1) TW371659B (OSRAM)
UA (1) UA48205C2 (OSRAM)
UY (1) UY24386A1 (OSRAM)
WO (1) WO1997023473A1 (OSRAM)
ZA (1) ZA9610737B (OSRAM)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9920548D0 (en) * 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
SK13632001A3 (sk) 2000-02-02 2002-06-04 Florida State University Research Foundation, Inc. C10 karbonátom substituované taxány ako protinádorové činidlá
CA2435730C (en) * 2001-02-24 2011-03-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1663153A4 (en) * 2003-05-20 2011-01-05 Aronex Pharmaceuticals Inc COMBINATION SCHEMOTHERAPY WITH A LIPOSOMAL PLATINUM COMPLEX
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1669358A1 (en) * 2004-12-07 2006-06-14 Aventis Pharma S.A. Cytotoxic agents comprising new taxanes
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CN109503584A (zh) 2006-05-04 2019-03-22 勃林格殷格翰国际有限公司 多晶型
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US20080207743A1 (en) * 2007-02-28 2008-08-28 Rodger Lamb Biologically Active Taxane Analogs and Methods of Treatment
EP3542801A1 (en) * 2007-08-17 2019-09-25 Boehringer Ingelheim International GmbH Purin derivatives for use in the treatment of fap-related diseases
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
PE20110297A1 (es) * 2008-08-15 2011-05-26 Boehringer Ingelheim Int Inhibidores de dpp-4 para la cicatrizacion de heridas
KR20110067096A (ko) 2008-09-10 2011-06-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 및 관련 상태를 치료하기 위한 병용 요법
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20120107080A (ko) 2009-11-27 2012-09-28 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
EA033415B1 (ru) 2010-05-05 2019-10-31 Boehringer Ingelheim Int Способы лечения ожирения, применение ингибитора dpp-4 в этих способах и способ лечения пациентов, страдающих диабетом типа 2
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
PL3517539T3 (pl) 2011-07-15 2023-04-24 Boehringer Ingelheim International Gmbh Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
EP2849754B1 (en) 2012-05-14 2022-09-14 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2014080251A1 (en) 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
FR3010839B1 (fr) * 2013-09-17 2017-04-21 Schneider Electric Ind Sas Dispositif de raccordement electrique d'au moins un conducteur dans une borne appartenant a un appareil electrique
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
WO2015127685A1 (en) 2014-02-28 2015-09-03 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
WO2015151081A2 (en) 2015-07-12 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
AU2017276758A1 (en) 2016-06-10 2018-11-08 Boehringer Ingelheim International Gmbh Combinations of Linagliptin and metformin
US12364767B2 (en) 2016-11-14 2025-07-22 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers
JP2024541058A (ja) 2021-11-03 2024-11-06 ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. 抗体の特異的共役

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2017724C1 (ru) * 1990-07-12 1994-08-15 Дзе Юниверсити оф Канзас Способ получения производных таксола
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
FR2678930B1 (fr) * 1991-07-10 1995-01-13 Rhone Poulenc Rorer Sa Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii.
RU2059631C1 (ru) * 1991-11-29 1996-05-10 Дзе Юниверсити оф Канзас Производные таксола и фармацевтическая композиция, обладающая противоопухолевой активностью
ES2134847T3 (es) * 1992-04-17 1999-10-16 Abbott Lab Derivados de taxol.
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
MX9307777A (es) * 1992-12-15 1994-07-29 Upjohn Co 7-HALO-Y 7ß, 8ß-METANO-TAXOLES, USO ANTINEOPLASTICO Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN.

Also Published As

Publication number Publication date
CN1205697A (zh) 1999-01-20
DE69630145D1 (de) 2003-10-30
AU1180997A (en) 1997-07-17
CO4520184A1 (es) 1997-10-15
FR2742751A1 (fr) 1997-06-27
OA10700A (fr) 2002-11-27
WO1997023473A1 (fr) 1997-07-03
PL327405A1 (en) 1998-12-07
PE25198A1 (es) 1998-05-10
RO116194B1 (ro) 2000-11-30
ATE250593T1 (de) 2003-10-15
HU225032B1 (en) 2006-05-29
EP0876362A1 (fr) 1998-11-11
HK1017895A1 (en) 1999-12-03
DE69630145T2 (de) 2004-07-15
TR199801179T2 (xx) 1998-10-21
BR9612135A (pt) 1999-07-13
TNSN96169A1 (fr) 2005-03-15
ES2202490T3 (es) 2004-04-01
KR19990076680A (ko) 1999-10-15
IL124994A (en) 2000-12-06
DZ2149A1 (fr) 2002-10-23
EA199800588A1 (ru) 1998-12-24
BG102569A (en) 1999-04-30
MA26412A1 (fr) 2004-12-20
ZA9610737B (en) 1997-06-27
AR005197A1 (es) 1999-04-14
UY24386A1 (es) 2001-08-27
US5728849A (en) 1998-03-17
CZ196198A3 (cs) 1998-09-16
NO982580L (no) 1998-06-05
IL124994A0 (en) 1999-01-26
EA001533B1 (ru) 2001-04-23
JP2000502671A (ja) 2000-03-07
MY113934A (en) 2002-06-29
MX9804688A (es) 1998-10-31
TW371659B (en) 1999-10-11
CZ294972B6 (cs) 2005-04-13
KR100500351B1 (ko) 2005-12-21
UA48205C2 (uk) 2002-08-15
SK85398A3 (en) 1998-11-04
PT876362E (pt) 2004-02-27
NO982580D0 (no) 1998-06-05
FR2742751B1 (fr) 1998-01-30
IN188680B (OSRAM) 2002-10-26
CA2238884A1 (fr) 1997-07-03
HUP9904046A3 (en) 2001-08-28
DK0876362T3 (da) 2004-02-02
HUP9904046A1 (hu) 2001-04-28
PL189311B1 (pl) 2005-07-29
BG63204B1 (bg) 2001-06-29
IN186768B (OSRAM) 2001-11-03
CN1103766C (zh) 2003-03-26
NZ324337A (en) 2000-03-27
EP0876362B1 (fr) 2003-09-24
CA2238884C (fr) 2007-02-06
IN188469B (OSRAM) 2002-09-28
SK282835B6 (sk) 2002-12-03
AU712597B2 (en) 1999-11-11
IN188470B (OSRAM) 2002-09-28
NO317358B1 (no) 2004-10-18

Similar Documents

Publication Publication Date Title
JP3953106B2 (ja) 新規なタキソイド、その製造及びそれを含有する製薬学的組成物
JP3790826B2 (ja) 新規なタキソイド、その製造及びそれを含有する製薬学的組成物
US5847170A (en) Taxoids, their preparation and pharmaceutical compositions containing them
JP4308905B2 (ja) 新規なタキソイド、その製造及びそれを含有する製薬学的組成物
AU715228B2 (en) Taxoids, preparation thereof and pharmaceutical compositions containing same
CN1073106C (zh) 新的紫杉化合物,其制备方法及其药物组合物
US6372780B2 (en) Methods of treating cell lines expressing multidrug resistance P-glycoprotein
AU704719B2 (en) Novel taxoids,their preparation and pharmaceutical compositions containing them
JPH10500979A (ja) 新規タキソイド類、その製造およびそれらを含む製薬学的組成物
SK157196A3 (en) Taxoids, preparation and pharmaceutical compositions containing them
US5968931A (en) Taxoids, preparation thereof and pharmaceutical compositions containing same
JPH10500981A (ja) 新規のタキソイド類、それらの製造、およびそれらを含む製薬学的組成物
HK1017895B (en) Novel taxoids, preparation thereof and pharmaceutical compositions containing same
MXPA96006227A (en) Novedous taxoids your preparation and the pharmaceutical compositions that contain them

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20061114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070207

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20070410

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20070424

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100511

Year of fee payment: 3

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100511

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110511

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110511

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120511

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130511

Year of fee payment: 6

LAPS Cancellation because of no payment of annual fees